Efficient Expression of an Alzheimer’s Disease Vaccine Candidate in the Microalga Schizochytrium sp. Using the Algevir System
Article
-
- Overview
-
- Research
-
- Identity
-
- Additional Document Info
-
- View All
-
Overview
abstract
-
Alzheimer’s disease (AD) is the most common neurodegenerative disease, where β-amyloid (Aβ) plays a key role in forming conglomerated senile plaques. The receptor of advanced glycation end products (RAGE) is considered a therapeutic target since it transports Aβ into the central nervous system, favoring the pathology progression. Due to the lack of effective therapies for AD, several therapeutic approaches are under development, being vaccines considered a promising alternative. Herein, the use of the Algevir system was explored to produce in the Schizochytrium sp. microalga the LTB:RAGE vaccine candidate. Algevir relies in an inducible geminiviral vector and led to yields of up to 380 µg LTB:RAGE/g fresh weight biomass at 48-h post-induction. The Schizochytrium-produced LTB:RAGE vaccine retained its antigenic activity and was highly stable up to temperatures of 60 °C. These data demonstrate the potential of Schizochytrium sp. as a platform for high production of thermostable recombinant antigens useful for vaccination against AD. © 2018 Springer Science Business Media, LLC, part of Springer Nature
-
Alzheimer’s disease (AD) is the most common neurodegenerative disease, where β-amyloid (Aβ) plays a key role in forming conglomerated senile plaques. The receptor of advanced glycation end products (RAGE) is considered a therapeutic target since it transports Aβ into the central nervous system, favoring the pathology progression. Due to the lack of effective therapies for AD, several therapeutic approaches are under development, being vaccines considered a promising alternative. Herein, the use of the Algevir system was explored to produce in the Schizochytrium sp. microalga the LTB:RAGE vaccine candidate. Algevir relies in an inducible geminiviral vector and led to yields of up to 380 µg LTB:RAGE/g fresh weight biomass at 48-h post-induction. The Schizochytrium-produced LTB:RAGE vaccine retained its antigenic activity and was highly stable up to temperatures of 60 °C. These data demonstrate the potential of Schizochytrium sp. as a platform for high production of thermostable recombinant antigens useful for vaccination against AD. © 2018 Springer Science%2bBusiness Media, LLC, part of Springer Nature
publication date
published in
Research
keywords
-
Algae-based vaccine; Alzheimer’s disease; Receptor for advanced glycation end products; Recombinant protein yield Algae; Antigens; Glycosylation; Neurodegenerative diseases; Recombinant proteins; Advanced glycation end products; Alzheimer; Central nervous systems; Effective therapy; Highly stables; Schizochytrium; Senile plaques; Therapeutic targets; Vaccines; advanced glycation end product receptor; Alzheimer disease vaccine; bacterial toxin; enterotoxin; epitope; Escherichia coli protein; fusion protein; heat-labile enterotoxin, E coli; Alzheimer disease; antagonists and inhibitors; chemistry; Escherichia coli; genetics; growth, development and aging; human; metabolism; microalga; molecular cloning; protein engineering; Alzheimer Disease; Alzheimer Vaccines; Bacterial Toxins; Cloning, Molecular; Enterotoxins; Epitopes; Escherichia coli; Escherichia coli Proteins; Humans; Microalgae; Protein Engineering; Receptor for Advanced Glycation End Products; Recombinant Fusion Proteins
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional Document Info